Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism

Essentials Recent randomized trials suggested fewer bleeding events in fragile patients with VTE receiving DOACs. The frequency, clinical characteristics and outcome of these patients have not been reported in real life. Fragile patients with VTE had a higher risk for major bleeding or death and a lower risk for recurrences than non‐fragile.

F. Dentali | G. Lessiani | L. Mazzolai | P. Prandoni | E. Grandone | P. Wells | L. Bertoletti | P. Verhamme | F. Moustafa | L. Jara-Palomares | M. Alfonso | D. Jiménez | F. García-Bragado | C. Font | R. Otero | M. Monreal | G. Barillari | P. Llamas | A. Merah | H. Décousus | A. Visoná | E. Grau | B. Brenner | T. Vanassche | R. Maida | A. Riera-Mestre | I. Mahé | D. Farge-Bancel | A. Hij | D. Mastroiacovo | R. Pesavento | J. Troya | R. Guijarro | P. Di Micco | M. Bosevski | D. Riesco | R. Parisi | O. Reig | A. Rivas | F. Uresandi | R. Duce | R. Lopez-reyes | J. Nieto | I. Casado | A. Villalobos | H. Bounameaux | J. del Toro | L. López‐Jiménez | C. Falgá | A. Skride | L. Font | P. Ruiz-Artacho | A. Ballaz | R. Valle | I. Tzoran | J. Trujillo-Santos | V. Gómez | A. Braester | M. Barrón | C. Fernández‐Capitán | M. Lorente | R. Malý | R. Barba | R. Quintavalla | M. Papadakis | E. Tiraferri | M. Zdraveska | A. Bura‐Riviere | J. Sahuquillo | D. Tonello | Á. Blanco‐Molina | R. Poggio | B. Valero | F. Pace | M. Giorgi Pierfranceschi | P. Wells | M. Ciammaichella | E. Usandizaga | C. Cattabiani | P. Dulíček | F. Bilora | G. Antonucci | E. Imbalzano | B. Sopeña | M. Rodríguez-Davila | E. Bucherini | N. Ruíz-Giménez | J. Jiménez | V. Rosa | A. Lorenzo | R. Del Pozo | O. Gavín | M. García | M. Pinelli | A. Reis | A. Samperiz | M. Adarraga | B. Barrón‐Andrés | I. Cañas | L. Hernández-Blasco | M. Joya | F. Martín-Martos | M. Mellado | S. Soler | J. Vela | J. Hirmerová | E. Salgado | A. Rocci | V. Ģībietis | C. Bortoluzzi | M. Pellegrinet | C. Tolosa | P. Gallego | M. Lumbierres | J. Bascuñana | N. Chic | M. Díaz‐Pedroche | J. López‐Sáez | J. Suriñach | B. Brandolin | Hervé Paolo Benjamin Raquel Laurent Inna Abilio Marijan Decousus Prandoni Brenner Barba Bertoletti | P. Agudo | M. Aibar | J. Arcelus | J. Díaz‐Peromingo | C. Fernández-Aracil | M. Fidalgo | C. Gómez | J. González | A. Grimón | L. Guirado | J. Gutiérrez | G. Hernández‐Comes | M. Jaras | J.M.G. Lobo | P. López | J. Luque | P. Marchena | S. Nieto | A. Nuñez | M. Núñez | S. Otalora | J. Pedrajas | G. Pérez | C. Pérez‐Ductor | M. Peris | I. Pons | J. Porras | M. Rodriguez | E. Rosillo‐Hernández | M. Sala‐Sainz | R. Sánchez-Martínez | O. Sanz | M. Torres | L. Vela | M. Vicente | B. Xifré | Hhb Yoo | N. Dell'Elce | A. Tufano | B. Vitola | A. Visonà | B. Brenner | L. López-Jiménez | F. García‐Bragado | A. Bura‐Rivière | Raquel Barba | Inna Tzoran | Marijan Bosevski | Radovan Malý | R Barba | M. Rodríguez | R Malý | I Tzoran | M Bosevski | A. Bura-Rivière | P. Prandoni | J. Díaz-Peromingo | M.A. García | B. Brenner | R. Barba | L. Bertoletti | H. Bounameaux | P. Wells | H.H.B. Yoo

[1]  G. Agnelli,et al.  Treatment of Venous Thromboembolism With New Anticoagulant Agents. , 2016, Journal of the American College of Cardiology.

[2]  R. Yusen,et al.  Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. , 2016, Journal of the American College of Cardiology.

[3]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[4]  P. Dobesh,et al.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism , 2016, Journal of Thrombosis and Thrombolysis.

[5]  L. Mazzolai,et al.  Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism , 2015, Medicine.

[6]  M. Monreal,et al.  VTE Registry: What Can Be Learned from RIETE? , 2014, Rambam Maimonides medical journal.

[7]  R. Yusen,et al.  Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. , 2014, Journal of the American College of Cardiology.

[8]  M. Prins,et al.  Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies , 2013, Thrombosis Journal.

[9]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[10]  Marc Moss,et al.  Simple frailty score predicts postoperative complications across surgical specialties. , 2013, American journal of surgery.

[11]  G. Raskob,et al.  Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies , 2013, Thrombosis Journal.

[12]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[13]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[14]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[15]  M. Monreal,et al.  Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. , 2011, Journal of vascular surgery.

[16]  K. Wołkowska.  Summary of the article: Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous tromboemolism. N Engl J Med, 2010; 363: 2499-2510 , 2011 .

[17]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[18]  J. Nunnelee.  Review of an Article: Dabigatran versus warfarin in the treatment of acute venous thromboembolism (2009). Schulman S, Kearon C, Kakkar A, et al., N Engl J Med 361;2342-2352. , 2010, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[19]  P. Prandoni,et al.  Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry , 2010, Journal of thrombosis and haemostasis : JTH.

[20]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[21]  Thomas N. Robinson,et al.  Redefining Geriatric Preoperative Assessment Using Frailty, Disability and Co-Morbidity , 2009, Annals of surgery.

[22]  S. Matthews,et al.  The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. , 2008, Age and ageing.

[23]  M. Monreal,et al.  Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry , 2008, Thrombosis and Haemostasis.

[24]  I. McDowell,et al.  A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.

[25]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[26]  R. Yusen,et al.  Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease , 2001, Annals of Internal Medicine.

[27]  M. Prins,et al.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. , 1999, Archives of internal medicine.

[28]  R. Beyth,et al.  Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. , 1993, The American journal of medicine.

[29]  E. Wagner,et al.  Preventing frail health. , 1992, Clinics in geriatric medicine.

[30]  L Goldman,et al.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. , 1989, The American journal of medicine.

[31]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.